AMAG reports third one fourth total revenues of $17.6 million AMAG Pharmaceuticals, Inc. today reported unaudited consolidated economic results for the third quarter ended September 30, 2011 traitement ed . Additionally, AMAG announced leadership changes, including the departure of the company’s president and ceo, Brian J.G. Pereira, MD, and the execution of a broad restructuring plan to reduce operating expenses. As of September 30, 2011, the company’s cash, cash equivalents and investments totaled approximately $251 million. Pereira has resigned from his placement as president, CEO and a director of the ongoing company, effective immediately.
AMGA’s prestigious Acclaim Award honors companies that embrace the Institute of Medicine’s aims by incorporating the six attributes of an ideal healthcare delivery system as determined by the Commonwealth Fund Commission on a higher Performance Health Program. The award highlights the continued investigation and study toward finding the finest types of medical management, coordination of care delivery, and a systemic approach to improving the individual experience. The recipient of a Steuben can be received by the award Crystal, produced specifically for the award, in addition to national recognition. Honorees also are regarded and receive crystal awards. Applicant criteria, organized around the six IOM Aims for the 21st Century, place a heavy focus on leadership involvement.